Avadel Pharmaceuticals

AI Score

0

Unlock

8.48
0.07 (0.83%)
At close: Feb 20, 2025, 3:59 PM
8.45
-0.41%
After-hours: Feb 20, 2025, 05:35 PM EST
undefined%
Bid 8.2
Market Cap 817.63M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.75
PE Ratio (ttm) -11.31
Forward PE n/a
Analyst Buy
Ask 8.87
Volume 821,113
Avg. Volume (20D) 1,402,627
Open 8.39
Previous Close 8.41
Day's Range 8.27 - 8.53
52-Week Range 7.39 - 19.09
Beta undefined

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorpo...

Sector Healthcare
IPO Date Jun 7, 1996
Employees 154
Stock Exchange NASDAQ
Ticker Symbol AVDL
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for AVDL stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 123.92% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Avadel Pharmaceuticals is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.57%
Avadel Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription
3 months ago
-8.59%
Avadel Pharmaceuticals shares are trading lower after HC Wainwright maintained a Buy rating on the stock and cut its price target from $27 to $25.